Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure: A Randomized Control Trial

NCT06957366 is registered in ClinicalTrials.gov with McMaster University as lead sponsor.

NCT NCT06957366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06957366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure: A Randomized Control Trial
Lead sponsor
McMaster University
Phase
Not applicable
Overall status
Recruiting
Start date
April 1, 2025
Completion date
December 31, 2027
Enrollment
920 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af), vte